INT7475

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1981
Last Reported 2010
Negated 7
Speculated 2
Reported most in Body
Documents 138
Total Number 175
Disease Relevance 175.81
Pain Relevance 15.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma 12
liver 5
platelet 3
fats 3
plaque 3
Hdl1 (Mus musculus)
Pain Link Frequency Relevance Heat
alcohol 623 99.82 Very High Very High Very High
agonist 1850 99.78 Very High Very High Very High
Catecholamine 5 99.72 Very High Very High Very High
rheumatoid arthritis 38 99.68 Very High Very High Very High
Inflammation 1435 99.64 Very High Very High Very High
Bile 484 99.52 Very High Very High Very High
antagonist 194 99.42 Very High Very High Very High
Inflammatory response 56 99.36 Very High Very High Very High
cva 25 99.10 Very High Very High Very High
peptic ulcer disease 3 98.62 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 27014 100.00 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

567 100.00 Very High Very High Very High
Insulin Resistance 404 100.00 Very High Very High Very High
Pressure And Volume Under Development 216 100.00 Very High Very High Very High
Abdominal Obesity 50 100.00 Very High Very High Very High
Coronary Artery Disease 595 99.96 Very High Very High Very High
Hypertriglyceridemia 210 99.88 Very High Very High Very High
Renal Disease 51 99.84 Very High Very High Very High
Nicotine Addiction 693 99.72 Very High Very High Very High
Diabetes Mellitus 1267 99.70 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Moreover, cardiovascular benefits have also been identified with almond oil elevating the levels of so-called 'good cholesterol', high-density lipoproteins (HDL), whilst it reduces low-density lipoproteins (LDL).
Positive_regulation (elevating) of HDL associated with disorder of lipid metabolism
1) Confidence 0.67 Published 2010 Journal Complement Ther Clin Pract Section Abstract Doc Link 20129403 Disease Relevance 0.71 Pain Relevance 0.18
Cilostazol, a potent platelet inhibitor and vasodilator, lowers triglycerides and increases HDL concentrations in addition to increasing walking distance in patients with intermittent claudication.
Positive_regulation (increases) of HDL in platelet associated with restless leg syndrome and disorder of lipid metabolism
2) Confidence 0.58 Published 2003 Journal Atherosclerosis Section Abstract Doc Link 14644405 Disease Relevance 0.55 Pain Relevance 0.27
After completion of the run-in, patients (N = 752) continued with atorvastatin therapy (10, 20, 40, or 80 mg) and were randomized to receive either torcetrapib 60 mg or placebo.28 After 24 months of treatment, patients in the torcetrapib/atorvastatin group had a 63% increase in HDL and a 18% decrease in LDL compared with patients receiving atorvastatin monotherapy (P < 0.0001).
Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
3) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.33 Pain Relevance 0
One of the pharmacologic approaches that have recently undergone clinical evaluation in the randomized trials includes attempts at elevation of HDL level through the inhibition of the enzyme, CETP.
Positive_regulation (elevation) of HDL associated with disorder of lipid metabolism
4) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.84 Pain Relevance 0
This information in the recent years led to intense interest in the development of CETP inhibitors as therapeutic agents for raising HDL.27,28 Individuals homozygous for the CETP mutation that leads to its dysfunction or deficiency, have been shown to be associated with elevations in HDL exceeding 100%, along with more than 40% decrease in the level of LDL and apo-B as compared with familial controls.
Positive_regulation (elevations) of HDL associated with disorder of lipid metabolism
5) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.10 Pain Relevance 0
Statins are recommended as the first line of therapy; however, combination therapy is recommended for patients on statin therapy who also have low HDL or elevated non-HDL, especially if apo B levels are also high.
Positive_regulation (elevated) of HDL associated with disorder of lipid metabolism
6) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.60 Pain Relevance 0
Thus, while a 1 SD increase in HDL was associated with a 23% reduction in AMI risk in other Asians, it caused a mere a 13% risk reduction in the South Asians.
Positive_regulation (increase) of HDL in mere associated with myocardial infarction and disorder of lipid metabolism
7) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.45 Pain Relevance 0
Genetic mutations causing CETP deficiency result in increased levels of HDL.
Positive_regulation (increased) of HDL associated with disorder of lipid metabolism
8) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.04 Pain Relevance 0
Although statin therapy has an established efficacy in increasing HDL levels, only minor overall increases in HDL have been demonstrated.
Positive_regulation (increasing) of HDL associated with disorder of lipid metabolism
9) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.56 Pain Relevance 0.03
Although statin therapy has an established efficacy in increasing HDL levels, only minor overall increases in HDL have been demonstrated.
Positive_regulation (increases) of HDL associated with disorder of lipid metabolism
10) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.55 Pain Relevance 0.03
For example, cholesterol-fed rabbits that were treated with the CETP inhibitor, torcetrapib, exhibited 4-fold increases in HDL associated with a 60% reduction in atherosclerosis.


Positive_regulation (increases) of HDL associated with atherosclerosis and disorder of lipid metabolism
11) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.10 Pain Relevance 0
At the end of two years of follow-up, patients receiving torcetrapib showed a significant 61% increase in HDL, and a 20% reduction in LDL compared with those who received atorvastatin monotherapy.
Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
12) Confidence 0.50 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.07 Pain Relevance 0.03
Furthermore, while the presence of higher levels of HDL correlated with a decreased risk of AMI, the extent of decrease in risk seemed to be less prominent for South Asians than for other Asians (odds ratio for 1 SD elevation in HDL 0.87 in South Asians vs 0.77 in others.
Positive_regulation (elevation) of HDL associated with myocardial infarction and disorder of lipid metabolism
13) Confidence 0.44 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.40 Pain Relevance 0
In summary, the addition of torcetrapib to background atorvastatin therapy did not have a significant effect on atherosclerosis progression as measured by vascular imaging techniques in the ILLUSTRATE, RADIANCE 1, and RADIANCE 2 trials, despite substantial increases in HDL.
Neg (not) Positive_regulation (increases) of HDL associated with atherosclerosis, imagery and disorder of lipid metabolism
14) Confidence 0.44 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.82 Pain Relevance 0.10
Cilostazol also reduced triglyceride concentrations significantly (from 2.32+/-1.46 to 1.79+/-0.72 mmol/l, P < 0.01, in the cilostazol group versus 2.38 +/- 1.39 to 2.25 +/- 1.19 mmol/l in the placebo group) and increased HDL cholesterol concentrations (from 1.06 +/- 0.23 to 1.24 +/- 0.34 mmol/l, P < 0.001) in the cilostazol group versus no significant change (1.06 +/- 0.34 to 1.09 +/- 0.36 mmol/l) in the placebo group.
Positive_regulation (increased) of HDL
15) Confidence 0.39 Published 2003 Journal Atherosclerosis Section Body Doc Link 14644405 Disease Relevance 0.05 Pain Relevance 0
Once cholesterol gets associated with HDL, it becomes esterified through the action of another enzyme, LCAT.13 Cholesterol ester, thus produced, is, again, hydrophobic and it accumulates to the center of the lipoprotein molecule, producing mature HDL.14 Subsequently, the mature HDL is transported to the liver where it releases the cholesterol for excretion into the bile.
Positive_regulation (transported) of HDL in liver associated with bile and disorder of lipid metabolism
16) Confidence 0.36 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.80 Pain Relevance 0.13
These helical regions in the apolipoprotein of the HDL, apo A-1, similarly allows HDL to dock with the cell surface receptors ABCA-1 and SR-BI.
Positive_regulation (allows) of HDL associated with disorder of lipid metabolism
17) Confidence 0.36 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.75 Pain Relevance 0.25
Selective uptake of HDL by the liver is mediated by the hepatic receptor, scavenger receptor class B type 1 (SR-B1).
Positive_regulation (uptake) of HDL in liver associated with disorder of lipid metabolism
18) Confidence 0.36 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.86 Pain Relevance 0.14
According to the ATP III, if a patientÂ’s TG levels are below 200 mg/dL and the HDL is low (isolated low HDL), the administration of drugs that increase HDL (fibrates or nicotinic acid) can be considered.
Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
19) Confidence 0.36 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 1.31 Pain Relevance 0
More interestingly, a statistically significant inverse correlation between the increase in HDL and the regression of CIMT (P = 0.002) was noted suggesting that raising HDL with niacin ER over and above the statin treatment may account for the beneficial effect of atherosclerosis regression encountered.


Positive_regulation (increase) of HDL associated with atherosclerosis and disorder of lipid metabolism
20) Confidence 0.36 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.83 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox